CYP2C9*8is prevalent among African–Americans: implications for pharmacogenetic dosing

Kidney Function Influences Warfarin Responsiveness and Hemorrhagic Complications

(2009) N. A. Limdi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

(2009) Fumihiko Takeuchi et al.   PLoS Genetics

Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish Populations

(2008) Stuart A. Scott et al.   AMERICAN JOURNAL OF HUMAN GENETICS

CYP4F2 genetic variant alters required warfarin dose

(2008) M. D. Caldwell et al.   BLOOD

VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals

(2008) E. Aklillu et al.   BLOOD

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement

(2008) D. Wang et al.   BLOOD

The largest prospective warfarin-treated cohort supports genetic forecasting

(2008) M. Wadelius et al.   BLOOD

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

(2008) BF Gage et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans

(2008) H Schelleman et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Warfarin therapy: in need of improvement after all these years

(2008) Stephen E Kimmel   EXPERT OPINION ON PHARMACOTHERAPY

Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions inVKORC1

(2008) D. J. HARRINGTON et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans

(2008) L. BODIN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

VKORC1polymorphisms, haplotypes and haplotype groups on warfarin dose among African–Americans and European–Americans

(2008) Nita A Limdi et al.   PHARMACOGENOMICS

Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics

(2008) Hedi Schelleman et al.   PHARMACOGENOMICS

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations

(2008) Alan HB Wu et al.   PHARMACOGENOMICS

Influence ofCYP2C9andVKORC1on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans

(2008) Nita A Limdi et al.   PHARMACOGENOMICS

Warfarin Pharmacogenetics

(2008) Nita A Limdi et al.   PHARMACOTHERAPY